Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PSC 100

Drug Profile

PSC 100

Alternative Names: HPDSC; Human placenta-derived stem cells; Placental-derived stem cell therapy - Celularity; PSC-100; UCB + HPDSC; UCB and HPDSC

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation; Human Longevity
  • Developer Celgene Corporation; Celularity; Human Longevity; New York Medical College
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological disorders; Haematological malignancies
  • Preclinical Epidermolysis bullosa; Inflammation
  • Research Muscular atrophy

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 24 Jul 2018 Phase I development in Haematological malignancies and Haematological disorders is ongoing in USA (IV) (Celularity pipeline, July 2018)
  • 01 May 2018 Preclinical trials in Epidermolysis bullosa in USA (unspecified route), before May 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top